CV death among SGLT2i users versus non-users in subgroups stratified by CKD stages
| CV death | SGLT2i users | SGLT2i non-users | HR (95% CI) | P for interaction | ||||
| n/N | % | Rate/1000 person-years | n/N | % | Rate/1000 person-years | |||
| All patients | 34/3704 | 0.9 | 4.9 | 408/3704 | 11.0 | 25.6 | 0.173 (0.121 to 0.248) | |
| G1: eGFR ≥90 | 1/583 | 0.2 | 0.9 | 6/270 | 2.2 | 4.0 | 0.320 (0.032 to 3.190) | <0.001 |
| G2: eGFR≥60<90 | 13/1711 | 0.8 | 4.0 | 53/1315 | 4.0 | 7.5 | 1.151 (0.565 to 2.345) | |
| G3a: eGFR≥45<60 | 8/852 | 0.9 | 5.3 | 76/833 | 9.1 | 18.9 | 0.394 (0.183 to 0.846) | |
| G3b: eGFR≥30<45 | 5/409 | 1.2 | 6.6 | 108/564 | 19.1 | 52.8 | 0.137 (0.055 to 0.338) | |
| G4: eGFR≥15<30 | 7/115 | 6.1 | 35.4 | 93/422 | 22.0 | 94.3 | 0.368 (0.170 to 0.797) | |
| G5: eGFR <15 | 0/34 | 0 | 0 | 72/300 | 24.0 | 251.8 | 0.034 (0.002 to 0.462) | |
*CKD stages defined by eGFR (mL/min/1.73 m2).
CKD, chronic kidney disease; CV, cardiovascular; eGFR, estimated glomerular filtration rate; SGLT2i, sodium-glucose cotransporter 2 inhibitors.